19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

Cystic Fibrosis Clinical Trial

Official title:

19F Magnetic Resonance Imaging of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03497117
• Other study ID #: 15-0239
• Secondary ID: 2P30DK065988-11
• Status: Terminated
• Phase: Early Phase 1
• Start date: August 25, 2015
• Est. completion date: September 13, 2019

Study information

• Verified date: October 2020
• Source: University of North Carolina, Chapel Hill
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to use perfluorinated gas imaging to highlight regions of functional variation within the lungs of participants with cystic fibrosis (CF), and to correlate this with changes in spirometry, lung clearance index, and quality of life of CF subjects undergoing treatment for a pulmonary exacerbation.

Description:

The investigators hypothesize that 19F-enhanced MRI will detect improvements in lung ventilation following the treatment of a CF pulmonary exacerbation, and changes in ventilation as well as global MRI scores will track with both spirometry and quality of life assessments. Therefore, investigators propose this pilot and feasibility study to gain preliminary data on a comparison of the changes in ventilation that occur with treatment of a pulmonary exacerbation, as well as to begin to understand the repeatability of this novel outcome measure. Through this study, the investigators aim to: 1) Compare quantitative and qualitative assessments of lung ventilation using 19F MRI imaging and traditional, global physiologic assessments (spirometry, LCI) and compare these with images obtained in an age-matched healthy control population; 2) Correlate changes in MRI scoring with subjective changes in health related outcomes as measured by the CFQ-R (Cystic Fibrosis Questionnaire - Revised); 3) Determine the ability of 19F MRI to detect changes in ventilation that occur with treatment of a CF pulmonary exacerbation; and 4) Determine the repeatability of 19F MRI assessment of ventilation in a disease population.

Participants with CF with baseline forced expiratory volume in 1 second (FEV1) of at least 40%, no contraindications to MRI, and oxygen saturation >90% on room air will be prospectively enrolled. Investigators will recruit a pre-defined cross-section of CF patients with mild, moderate, and severe lung disease, with approximately 4 subjects per group at the onset of a disease exacerbation requiring antibiotic intervention. The research team will obtain a pre-response MRI (within 3 days of initiating oral, inhaled, or IV antibiotic therapy), and a post-treatment MRI (within 3 days of terminating antibiotic treatment) to assess the responsiveness of 19F-MRI to a change in disease status. Each 19F-MRI study will be combined with assessments of spirometry, LCI (multiple breath nitrogen washout), and quality of life (CFQ-R quality of life tool).

19F-MRI will be performed by having each participant inhale a mixture of 79% perfluorinated propane (PFP) and 21% oxygen (pre-mixed) while using MRI to obtain 3D images. Subsequently, participants will be switched to room air, and cycled breathing will be continued while additional MRI images are captured to characterize gas wash-out. Safety measures, including pulse oximetry, will be monitored continuously, and spirometry will be performed before and after each MRI. Participants will also perform multiple breath washout maneuvers to obtain a lung clearance index, so this may be correlated to wash-out kinetics of the PFP.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: September 13, 2019
• Est. primary completion date: September 13, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Non-smokers (<10 pack year history and no active smoking in the past year);

• Diagnosis of cystic fibrosis via standard sweat chloride/phenotypic features/genotyping

• Able to reproducibly perform lung function testing and have an FEV1 >30% of predicted at screening.

• No requirement for supplemental oxygen

• Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.

• Participants must be willing and able to comply with scheduled visits and other trial procedures.

• Diagnosis of a pulmonary exacerbation according to Fuchs criteria (4 of the following 12 signs and symptoms) deemed to require antibiotic treatment, and must also include the change in lung function criterion:

• Change in sputum

• New or increased hemoptysis

• Increased cough

• Increased dyspnea

• Malaise, fatigue, or lethargy

• Temperature above 38deg C

• Anorexia or weight loss

• Sinus pain or tenderness

• Change in sinus discharge

• Change in physical examination of the chest

• Decrease in pulmonary function by 10% or more from a previously recorded value

• Radiographic change indicative of pulmonary infection

Exclusion Criteria:

• Under 18 years of age

• Active or former smokers with less than 1 years since quitting, or >10 pack-year smoking history

• Active asthma flare, as perceived by the study physician or unstable asthma characterized by advancement of asthma therapy in the last month or two courses of oral steroids in the past six months.

• Unable to undergo a 3.0-Tesla MRI of lungs and chest because of contraindications including

1. Occupation (past or present) of machinist, welder, grinder

2. Injury to the eye involving a metallic object

3. Injury to the body by a metallic object (bullet, BB, shrapnel)

4. Presence of a cardiac pacemaker or defibrillator

5. Presence of aneurysm clips

6. Presence of carotid artery vascular clamp

7. Presence of neurostimulator

8. Presence of insulin or infusion pump

9. Presence of implanted drug infusion device that is not known to be MRI compatible (i.e., was placed outside of University of North Carolina Hospitals (UNCH) or is older than 10 years)

10. Bone growth or fusion simulator

11. Presence of cochlear, otologic or ear implant

12. Any type of prosthesis (eye, penile, etc.)

13. Artificial limb or joint

14. Non-removable electrodes (on body, head or brain)

15. Intravascular stents, filters or coils

16. Shunt (spinal or intraventricular)

17. Swan-Ganz catheter

18. Any implant held in place by a magnet

19. Transdermal delivery system (e.g. Nitro)

20. Intrauterine device (IUD) or diaphragm

21. Tattooed makeup (eyeliner, lips, etc.) or tattoos covering >25% of body surface area

22. Body piercings (MUST BE REMOVED BEFORE MRI)

23. Any metal fragments

24. Internal pacing wires

25. Metal or wire mesh implants

26. Hearing aid (REMOVE BEFORE MRI) aa. Dentures (REMOVE BEFORE MRI) bb. Claustrophobia

• Unable to tolerate inhalation of the gas mixture

• Unable to adequately complete other study measures, including spirometry and multiple breath nitrogen washout

• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the PI, would make the participant inappropriate for enrollment.

• Pregnancy; women of childbearing potential must have a confirmed negative serum pregnancy test at screening, and a negative urine test on the day of the MRI scan, prior to the MRI scan (if serum test not performed the same day).

• Facial hair preventing a tight fit of the mask used in the study

• Allergy or intolerance due to side effects to bronchodilators

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Intervention

Device:
• Lung Clearance Index
To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.

Drug:
• MRI with PFP
Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas) Administration: Full-face disposable ventilation mask and a standard Douglas Bag system. Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition. Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.

Locations

Country	Name	City	State
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Couch MJ, Ball IK, Li T, Fox MS, Littlefield SL, Biman B, Albert MS. Pulmonary ultrashort echo time 19F MR imaging with inhaled fluorinated gas mixtures in healthy volunteers: feasibility. Radiology. 2013 Dec;269(3):903-9. doi: 10.1148/radiol.13130609. Epub 2013 Oct 28. — View Citation

Halaweish AF, Moon RE, Foster WM, Soher BJ, McAdams HP, MacFall JR, Ainslie MD, MacIntyre NR, Charles HC. Perfluoropropane gas as a magnetic resonance lung imaging contrast agent in humans. Chest. 2013 Oct;144(4):1300-1310. doi: 10.1378/chest.12-2597. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Whole lung ventilation defect volume (VDV)	To obtain ventilation defect volumes (VDVs), investigators will use the final wash-in image to identify all regions of interest having a signal intensity below the pre-defined threshold which indicates poor ventilation. The combined volume of all these 'ventilation defect' regions will be computed to obtain the VDV.	1 day
Secondary	The wash-in kinetics of PFP	For each participant, an exponential model will be fit to obtain a statistical estimate, T, of the rate constant that characterizes the kinetics of gas wash-in. Aggregating across all participants, the frequency distributions of T values will be characterized by tabulating estimates of the mean and standard deviation (SD). Corresponding 95% confidence intervals and the minimum, maximum, and interquartile range of T values will also be tabulated.	1 day
Secondary	Ventilation defect percent (VDP) correlation with LCI	Changes in VDP from pre/post treatment will be correlated with changes in LCI pre- and post-exacerbation.	1 day
Secondary	Ventilation defect percent (VDP) correlation with FEV1	Changes in VDP from pre/post treatment will be correlated with changes in FEV1 pre- and post- exacerbation.	1 day